enGene (NASDAQ:ENGN) Stock Price Breaks Below Fifty Day Moving Average – Here’s What Happened

Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $1.79 and traded as low as $1.76. enGene shares last traded at $1.76, with a volume of 1,008,041 shares trading hands.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ENGN shares. Citigroup lowered shares of enGene from a “market perform” rating to a “hold” rating in a research note on Friday, October 16th. HC Wainwright restated a “buy” rating on shares of enGene in a research report on Friday, October 16th. Jefferies Financial Group raised shares of enGene to a “strong-buy” rating in a report on Tuesday, October 13th. Raymond James Financial reaffirmed an “outperform” rating on shares of enGene in a research report on Thursday, November 12th. Finally, Citizens Jmp reiterated a “market perform” rating on shares of enGene in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.75.

Read Our Latest Research Report on enGene

enGene Trading Down 3.1%

The company has a quick ratio of 10.21, a current ratio of 10.21 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average is $1.79 and its 200 day moving average is $3.77. The company has a market cap of $114.27 million, a price-to-earnings ratio of -0.82 and a beta of -0.24.

enGene (NASDAQ:ENGN – Get Free Report) last posted its earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). Research analysts predict that enGene Holdings Inc. will post -1.82 EPS for the current year.

Institutional Trading of enGene

A number of institutional investors and hedge funds have recently made changes to their positions in the business. SR One Capital Management LP purchased a new position in shares of enGene during the 2nd quarter valued at approximately $1,293,607. Siren L.L.C. increased its holdings in enGene by 57.5% in the 1st quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock worth $35,774,000 after acquiring an additional 1,916,895 shares in the last quarter. Eversept Partners LP increased its holdings in enGene by 12.0% in the 1st quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock worth $3,477,000 after acquiring an additional 54,708 shares in the last quarter. Renaissance Technologies LLC raised its position in enGene by 651.1% during the first quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock worth $1,063,000 after acquiring an additional 135,318 shares during the period. Finally, Sei Investments Co. acquired a new position in enGene during the first quarter worth $409,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

About enGene

(Get Free Report)

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Further Reading

Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.